Every Form 4 that Outlook Therapeutics, Inc. (OTLK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OTLK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OTLK filings page.
Outlook Therapeutics, Inc. (OTLK) reported that its Chief Financial Officer, Kevin Michael Lundquist, received a grant of 500,000 employee stock options on September 1, 2026. The options have an exercise price of $0.63 per share and expire on September 1, 2036. The grant was made as an inducement to his employment under Nasdaq Listing Rule 5635(c)(4) and vests 25% on September 1, 2027, with the remainder vesting in equal monthly installments over the following three years, subject to his continuous service.
Outlook Therapeutics, Inc. director and Chief Executive Officer Robert Charles Jahr purchased 151,515 shares of common stock and 151,515 accompanying warrants on August 14, 2026 in an underwritten public offering at a combined public offering price of $0.99 per share and warrant. The warrants are exercisable immediately at $1.10 per share and expire on August 14, 2031. Following these transactions, Jahr holds 151,515 common shares and 151,515 warrants directly.
Outlook Therapeutics, Inc. insider GMS Ventures & Investments, associated with director and 10% owner Ghiath M. Sukhtian, participated in an underwritten public offering on August 12, 2026. GMS Ventures purchased 2,525,252 shares of common stock at $0.99 per share and received accompanying warrants to purchase 2,525,252 shares of common stock at an exercise price of $1.10 per share. The warrants were issued for $0.00 as part of the combined public offering price, are exercisable immediately, and expire on August 14, 2031 subject to a beneficial ownership limitation. Following the stock purchase, GMS Ventures held 24,617,320 shares of Outlook Therapeutics common stock indirectly reported for Sukhtian, with both reporting persons disclaiming beneficial ownership beyond their pecuniary interest.
Outlook Therapeutics, Inc. director and Chief Financial Officer Lawrence A. Kenyon reported open-market-style purchases tied to an underwritten public offering on August 14, 2026. He acquired 101,010 shares of common stock plus accompanying warrants to purchase another 101,010 shares, for a combined public offering price of $0.99 per share and warrant. The warrants are immediately exercisable at $1.10 per share and expire on August 14, 2031. Following the stock purchase, he held 106,956 common shares directly.
Outlook Therapeutics director Faisal Ghiath Sukhtian purchased 95,398 shares of common stock on July 29, 2026 at 1.0482 per share in an open-market or private transaction. After this buy, he directly owns 220,972 common shares. The transaction was not reported as made under a Rule 10b5-1 trading plan.
Outlook Therapeutics, Inc. reported that Chief Financial Officer Lawrence A. Kenyon received a grant of 210,078 stock options on July 21, 2026 under its 2024 Equity Incentive Plan. Each option covers one share of common stock at an exercise price of 1.4304 per share, vests in full on July 21, 2027, and expires on July 21, 2036, conditional on his continued service.
Outlook Therapeutics, Inc. reports that Chief Executive Officer Robert Charles Jahr received a grant of stock options covering 100,000 shares of common stock at an exercise price of $1.4304 per share. Granted on July 21, 2026 under the 2024 Equity Incentive Plan, the options vest in full on July 21, 2027 and expire on July 21, 2036, leaving him with 100,000 options held directly.
Outlook Therapeutics director Yezan Munther Haddadin bought 29,000 shares of Common Stock in an open-market purchase. The shares were acquired at an average price of $0.8326 per share. Following this transaction, he directly holds a total of 66,167 Outlook Therapeutics shares.
Outlook Therapeutics received a new investment from GMS Ventures & Investments, which bought 8,539,709 shares of common stock at $0.5855 per share in a registered direct offering for a total purchase price of about $5.0 million. Following this purchase, GMS Ventures reported indirect ownership of 22,092,068 common shares.
The filing also shows amendments to multiple warrant series held by GMS Ventures. Existing warrants with exercise prices of $2.26 and $1.40 per share were cancelled and replaced with new warrants covering the same share amounts at a reduced exercise price of $0.5855 per share, with expirations in 2030. The transactions are reported as cancellations of old warrants and acquisitions of new ones rather than exercises.
All securities are held of record by GMS Ventures. Ghiath M. Sukhtian controls GMS Ventures and may be deemed to share voting and investment power, but the reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest.
Outlook Therapeutics, Inc. director Sukhtian Faisal Ghiath reported an open-market purchase of 122,174 shares of Common Stock at an average price of $0.4093 per share. Following this transaction, he directly owns a total of 125,574 Common Stock shares.
Outlook Therapeutics, Inc. director Yezan Munther Haddadin reported an open-market purchase of the company’s Common Stock. On May 26, 2026, he bought 34,000 shares at $0.44 per share. Following this transaction, he directly owns 37,167 shares of Outlook Therapeutics common stock.
Outlook Therapeutics director buys shares on the open market. Director Randy H. Thurman purchased 5,000 shares of Outlook Therapeutics common stock in an open-market transaction at $0.429 per share. Following this trade, he directly holds a total of 5,593 shares of the company.
Outlook Therapeutics director Kurt J. Hilzinger increased his personal stake by buying 400,000 shares of Common Stock in an open-market purchase. The shares were acquired at an average price of $0.4413 per share. Following this transaction, he directly owns 423,655 shares of Outlook Therapeutics common stock.
Outlook Therapeutics, Inc. director Huang Andong received two stock option grants totaling 340,050 options: 286,734 options at an exercise price of $1.04 (granted 10/01/2025) and 53,316 options at $1.06 (granted 10/03/2025). The larger grant is an annual non-employee director award under the company's 2024 Equity Incentive Plan and fully vests on October 1, 2026 subject to continuous service.
The smaller grant was issued in lieu of $50,000 of cash fees and vests in four equal quarterly installments, finishing on September 30, 2026, subject to continuous service. Both option grants include acceleration upon a defined Change in Control if the reporting person remains in service immediately prior to that event.
Outlook Therapeutics director Julia A. Haller received two stock option grants reported on 10/01/2025 and 10/03/2025. The first grant is for 286,734 options with an exercise price of $1.04 that vest in full on 10/01/2026 subject to continued service and acceleration on a defined Change in Control. The second grant is for 58,648 options at $1.06, issued in lieu of $55,000 in cash fees and vesting in four equal quarterly installments through 9/30/2026, also subject to service and Change in Control acceleration.
Outlook Therapeutics director Kurt J. Hilzinger received two equity awards reported on 10/01/2025 and 10/03/2025. The filings show a stock option for 286,734 shares priced at $1.04 that vests in full on 10/01/2026 with acceleration on a Change in Control, and a stock option for 90,638 shares priced at $1.06 granted in lieu of $85,000 cash fees that vest in four equal quarterly installments ending 09/30/2026, also subject to Change in Control acceleration. Both option grants are held directly by the reporting person and have an expiration date of 10/01/2035 or 10/03/2035 respectively. The report was filed by one reporting person and signed by an attorney-in-fact on 10/03/2025.
Outlook Therapeutics director Julian S. Gangolli was granted a non‑employee director stock option on 10/01/2025 to buy 286,734 shares of common stock at an exercise price of $1.04 per share. The option is an annual grant under the company’s Non‑Employee Director Compensation Policy and the 2024 Equity Incentive Plan. The option shall fully vest on 10/01/2026 provided the director continues service through that date, and the underlying shares are subject to acceleration on a Change in Control if the director is in service immediately before such event. The filing was reported on Form 4 and signed by an attorney‑in‑fact on behalf of the reporting person.
Outlook Therapeutics, Inc. (OTLK) director Yezan Munther Haddadin reported two option grants. On 10/01/2025 he was granted 286,734 stock options with a $1.04 exercise price that, per the issuer, "shall fully vest on October 1, 2026" subject to continuous service and acceleration on a Change in Control. On 10/03/2025 he received 95,969 options with a $1.06 exercise price granted in lieu of $90,000 in cash fees; these vest in four equal quarterly installments and become fully vested on September 30, 2026, subject to continuous service and similar Change in Control acceleration. Both option grants expire in 2035 and are reported as direct beneficial ownership. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Outlook Therapeutics (OTLK) reported a director equity award on Form 4. The reporting person received a stock option for 286,734 shares at an exercise price of $1.04 on 10/01/2025. According to the disclosure, this annual grant under the 2024 Equity Incentive Plan vests in full on 10/01/2026, with potential acceleration upon a Change in Control.
A separate stock option for 58,648 shares at an exercise price of $1.06 was granted on 10/03/2025 in lieu of $55,000 of cash director fees. These options vest in four equal quarterly installments, fully vested by 09/30/2026, and are also subject to acceleration upon a Change in Control under the plan terms.
Outlook Therapeutics, Inc. (OTLK) reported stock option grants to director Faisal G. Sukhtian consisting of 286,734 options at an exercise price of $1.04 (grant date 10/01/2025) and 117,296 options at $1.06 (grant date 10/03/2025), for a total of 404,030 options. The first grant is an annual non-employee director award that fully vests on 10/01/2026 subject to continued service and accelerates upon a Change in Control. The second grant was issued in lieu of $110,000 in cash fees and vests in four equal quarterly installments, fully vesting on 09/30/2026, subject to continued service and Change in Control acceleration.